TCGA-GV-A3QH-01A-11R-A220-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 8.475689882
- os_event
- true
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.320
- E2F_TARGETS+0.300
- MYC_TARGETS_V2+0.270
- MITOTIC_SPINDLE+0.250
- INTERFERON_ALPHA_RESPONSE+0.230
- SPERMATOGENESIS+0.200
- UNFOLDED_PROTEIN_RESPONSE+0.080
- PROTEIN_SECRETION+0.030
- KRAS_SIGNALING_DN+0.020
- MYC_TARGETS_V1+0.000
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.590
- ALLOGRAFT_REJECTION-0.530
- COAGULATION-0.470
- ANGIOGENESIS-0.460
- INFLAMMATORY_RESPONSE-0.430
- COMPLEMENT-0.400
- P53_PATHWAY-0.400
- APICAL_JUNCTION-0.380
- APOPTOSIS-0.380
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR650141 | — | — | 0.862 |
| 2 | SAMN03290898 | — | — | 0.862 |
| 3 | C3N-02155 | — | cohortA3 | 0.861 |
| 4 | SRR650202 | — | — | 0.858 |
| 5 | 5af838ac-ab79-41c0-81fb-168cf9b1cf50 | — | — | 0.854 |
| 6 | ERR2208947 | — | — | 0.853 |
| 7 | C3N-02728 | — | cohortMD1 | 0.853 |
| 8 | TCGA-DK-AA6U-01A-11R-A39I-07 | — | — | 0.852 |
| 9 | SRR26320089 | — | — | 0.849 |
| 10 | SRR8942963 | — | — | 0.848 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.320 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.270 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.250 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.230 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.080 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.030 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.020 | Remibrutinib | — uncovered |